Page 3 - Technology Incubation Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The Association of Public and Land-grant Universities (APLU) honors UConn’s success as economic engine and innovation driver for the state and region.

-- RLYB212 Phase 1b Proof-of-Concept Study Results Presented at the 31st Congress of the International Society of Thrombosis and Haemostasis in June 2023 -- -- RLYB212 Phase 1 Multiple Dose Cohort...

 -- RLYB212 Demonstrated Dose-Dependent, Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects -- -- Mean Reduction in Platelet Elimination Half-Life After Subcutaneous Administration of RLYB212 was ≥90% in both RLYB212 Dose Groups, Achieving Proof-of-Concept Criteria -- -- Phase 2 Study in Pregnant Women at Higher Risk of HPA-1a Alloimmunization to be Initiated in 2H 2024 -- -- Phase 1 Multiple Dose Data and Maternal-Fetal Toxicology Data On-track for 4Q 2023 -- -- Company to Host Investor and Analyst Meeting Webcast with Corresponding Slid...

-- Data from the RLYB212 Phase 1b Proof-of-Concept Study to be Featured as an Oral Presentation at ISTH -- -- Company to Host Webcast Following ISTH Oral Presentation of RLYB212 --NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying a...

Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,... | June 1, 2023